NMN vs Urolithin A: What the Research Compares

Answer first: the two have not been tested against each other

Among the published work summarised on this page, no head-to-head trial administered nicotinamide mononucleotide (NMN) and urolithin A to the same participants or animals and compared outcomes between the two arms. That absence matters, because any comparison between them is therefore an exercise in placing two separate literatures side by side — different models, different endpoints, different measurement tools — rather than reading a result from a single study designed to rank them. Where this page describes a finding, the citation sits in the same sentence, and where the citation set cannot support a statement, the statement is simply left out.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision related to the compounds discussed here.

Different classes, different origins

NMN

NMN is a nucleotide built from a nicotinamide base, a ribose sugar and a phosphate group. It belongs to the family of NAD+ precursors — small molecules positioned upstream of nicotinamide adenine dinucleotide in salvage-pathway biochemistry. It is not a peptide, not a botanical extract and not a microbial metabolite. Interest in this class grew out of the broader observation, described in a 2026 translational-medicine review of mitochondrial ageing, that mitochondrial structure and function deteriorate with age and that energy-metabolism cofactors sit close to the centre of that decline (PMID 42032617).

Urolithin A

Urolithin A is not consumed directly in meaningful amounts in most diets. It is a metabolite produced by gut bacteria from ellagitannins and ellagic acid found in foods such as pomegranate and certain nuts and berries. Because the conversion depends on an individual's microbiome composition, the research literature has treated urolithin A itself — rather than its dietary precursors — as the molecule of interest. Mechanistically it has been investigated as a mitophagy-related compound: a 2025 Autophagy paper reported that urolithin A modulated inter-organellar communication and promoted calcium-dependent mitophagy in the context of healthy ageing (PMID 40944367).

Mechanism: supplying a cofactor versus clearing damaged mitochondria

The cleanest way to describe the contrast is by entry point. NMN sits in the supply side of the story — a precursor molecule in NAD+ metabolism, a cofactor system that a 2026 review placed among the mitochondrial processes that fail with age (PMID 42032617). Urolithin A sits on the quality-control side: the 2025 mechanistic study reported that it acted through calcium-dependent mitophagy and inter-organellar signalling rather than by donating a metabolic cofactor (PMID 40944367).

Mitophagy — the selective removal of damaged mitochondria — is itself a defined molecular pathway with its own genetics. Work outside the supplement literature has characterised what happens when that pathway underperforms: a 2022 study in Cell Death & Disease reported PINK1–parkin-mediated neuronal mitophagy deficiency in prion disease (PMID 35184140). Researchers cite that kind of disease-model work to explain why mitophagy became a target of interest at all, not as evidence about either NMN or urolithin A.

Side-by-side comparison

What the urolithin A literature measured

The urolithin A evidence base that this page can cite is mechanistic rather than clinical. The 2025 Autophagy study framed urolithin A as a modulator of communication between organelles and reported that calcium-dependent mitophagy was the route through which it influenced ageing-related endpoints (PMID 40944367). That is a statement about a pathway, measured in a laboratory system, and it does not establish an outcome in people.

Readers encountering urolithin A material elsewhere will see references to muscle endurance measures, mitochondrial gene-expression panels and plasma metabolite profiling. Those endpoints belong to studies outside this page's verified citation set, so they are not described here as findings. The honest summary is narrow: in the work cited here, researchers reported a mitophagy-linked mechanism (PMID 40944367), and the broader mitochondrial-ageing framework that gives the mechanism its rationale was laid out in a separate 2026 review (PMID 42032617).

What the NMN side of the comparison looks like

The NMN literature is larger in volume than the urolithin A mechanistic literature and includes rodent metabolic studies and small human trials of oral administration. None of those papers appear in the verified citation set behind this page, which means no NMN dose, duration or effect is stated here. Repeating numbers without a citation in the same passage would be exactly the kind of claim this site avoids. What can be said is structural: NMN research has clustered around NAD+ concentration measurements, insulin sensitivity, physical function and tissue-specific metabolic readouts, and the general premise — that mitochondrial and energy-metabolism decline is a feature of ageing — was set out in the 2026 mitochondrial review cited above (PMID 42032617).

Why direct comparison is difficult even in principle

Three obstacles recur whenever researchers discuss ranking longevity-adjacent compounds.

• Different endpoints. A trial measuring blood NAD+ and a trial measuring mitophagy markers are not measuring the same thing, so neither result converts into the other's currency.
• Different models. Cell systems, short-lived model organisms and human participants answer different questions. The 2025 urolithin A work was mechanistic in design (PMID 40944367), and mechanistic results do not substitute for clinical endpoints.
• Multi-pathway confounding. Ageing interventions frequently touch several pathways at once. A 2026 paper in Drug Design, Development and Therapy reported that the investigational compound SRN-901 extended lifespan and healthspan by targeting multiple ageing pathways (PMID 42011226), which illustrates how difficult it is to attribute an outcome to a single mechanism when several are engaged.

Regulatory status compared

In the United States, neither NMN nor urolithin A is an approved drug for any indication. The two sit in different administrative categories. The Food and Drug Administration has taken the position that NMN is excluded from the statutory definition of a dietary supplement because it was authorised for investigation as a new drug, a determination that affects how products containing it may lawfully be marketed. Urolithin A has instead travelled the food-ingredient route and has been the subject of Generally Recognized as Safe notifications for use in foods and beverages. Material sold to laboratories under research-use-only labelling is, by definition, not intended for human consumption regardless of the molecule involved. This is general regulatory information, not legal advice, and rules differ by country and change over time.

Tolerability and Adverse Events: What Studies Report

None of the papers cited on this page reported human adverse-event tables for either NMN or urolithin A. The 2025 urolithin A paper was a mechanistic investigation of calcium-dependent mitophagy and inter-organellar communication rather than a safety trial (PMID 40944367), the 2022 prion-disease paper examined PINK1–parkin mitophagy deficiency in a disease model and did not test either compound (PMID 35184140), and the 2026 lifespan study concerned a separate investigational compound (PMID 42011226). Because of that, this page makes no tolerability comparison between the two molecules; an absence of reported events in papers that never looked for them is not a safety finding.

How a real comparison would have to be built

1. A single protocol administering each compound to parallel arms, with a shared primary endpoint.
2. Endpoints that both mechanisms could plausibly move — for example mitochondrial function measures grounded in the ageing framework described in the 2026 review (PMID 42032617).
3. Sufficient duration and sample size for a difference between arms to be interpretable rather than incidental.
4. Pre-registration, so that a comparison is not assembled after the fact from unrelated studies.

Until something of that shape is published, statements that one compound outperforms the other are not drawn from comparative data. The most accurate description remains that researchers have studied two different molecules, from two different chemical classes, through two different mechanistic lenses onto the same ageing biology (PMID 40944367, PMID 42032617).

Related reading

• NMN: what the literature describes
• Urolithin A: what the literature describes

References

• Urolithin A modulates inter-organellar communication via calcium-dependent mitophagy to promote healthy ageing (Autophagy, 2025)
• Mitochondria at the heart of aging: structure, function, and failure (Journal of Translational Medicine, 2026)
• SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways (Drug Design, Development and Therapy, 2026)
• PINK1-parkin-mediated neuronal mitophagy deficiency in prion disease (Cell Death & Disease, 2022)